###begin article-title 0
###xml 86 91 <span type="species:ncbi:9606">human</span>
Clone-specific expression, transcriptional regulation, and action of interleukin-6 in human colon carcinoma cells
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 409 414 409 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 456 457 453 454 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 504 505 498 499 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
Many cancer cells produce interleukin-6 (IL-6), a cytokine that plays a role in growth stimulation, metastasis, and angiogenesis of secondary tumours in a variety of malignancies, including colorectal cancer. Effectiveness of IL-6 in this respect may depend on the quantity of basal and inducible IL-6 expressed as the tumour progresses through stages of malignancy. We therefore have evaluated the effect of IL-6 modulators, i.e. IL-1beta, prostaglandin E2, 17beta-estradiol, and 1,25-dihydroxyvitamin D3, on expression and synthesis of the cytokine at different stages of tumour progression.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 345 350 345 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 28 33 <span type="species:ncbi:9606">human</span>
We utilized cultures of the human colon carcinoma cell clones Caco-2/AQ, COGA-1A and COGA-13, all of which expressed differentiation and proliferation markers typical of distinct stages of tumour progression. IL-6 mRNA and protein levels were assayed by RT-PCR and ELISA, respectively. DNA sequencing was utilized to detect polymorphisms in the IL-6 gene promoter.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 344 347 338 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7 </sup>
###xml 470 475 461 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 646 651 637 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 760 764 751 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc </italic>
###xml 825 828 816 819 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8 </sup>
###xml 853 854 844 845 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
IL-6 mRNA and protein concentrations were low in well and moderately differentiated Caco-2/AQ and COGA-1A cells, but were high in poorly differentiated COGA-13 cells. Addition of IL-1beta (5 ng/ml) to a COGA-13 culture raised IL-6 production approximately thousandfold via a prostaglandin-independent mechanism. Addition of 17beta-estradiol (10-7 M) reduced basal IL-6 production by one-third, but IL-1beta-inducible IL-6 was unaffected. Search for polymorphisms in the IL-6 promoter revealed the presence of a single haplotype, i.e., -597A/-572G/-174C, in COGA-13 cells, which is associated with a high degree of transcriptional activity of the IL-6 gene. IL-6 blocked differentiation only in Caco-2/AQ cells and stimulated mitosis through up-regulation of c-myc proto-oncogene expression. These effects were inhibited by 10-8 M 1,25-dihydroxyvitamin D3.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 158 159 158 159 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 184 185 184 185 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 350 355 344 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 3 8 <span type="species:ncbi:9606">human</span>
In human colon carcinoma cells derived from well and moderately differentiated tumours, IL-6 expression is low and only marginally affected, if at all, by PGE2, 1,25-dihydroxyvitamin D3, and 17beta-estradiol. However, IL-6 is highly abundant in undifferentiated tumour cells and is effectively stimulated by IL-1beta. In case of overexpression of an IL-6 gene variant with extreme sensitivity to IL-1beta, massive release of the cytokine from undifferentiated tumour cells may accelerate progression towards malignancy by paracrine action on more differentiated tumour cells with a still functioning proliferative IL-6 signalling pathway.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 54 55 54 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 185 186 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 218 219 218 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 220 221 220 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 282 283 282 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 469 470 469 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 578 579 578 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 787 788 787 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 855 856 855 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 351 356 <span type="species:ncbi:9606">human</span>
Interleukin-6 (IL-6) is an immunomodulatory cytokine [1], which also plays a role in growth stimulation, metastasis, and angiogenesis in secondary tumours in a variety of malignancies [2], including colorectal cancer [3-7]. IL-6 can be released from tumour infiltrating leukocytes [8], but is produced to a large extent by tumour cells themselves: In human colon cancer, IL-6 expression parallels tumour progression, reaching a maximum in high grade cancerous lesions [5]. Only still differentiated colon carcinoma cells are responsive to the growth stimulatory action of IL-6 [5]. We therefore reasoned that IL-6, when released from rather undifferentiated colon carcinoma cells, may aid tumour progression by a paracrine-induced proliferation of still differentiated neoplastic cells [5]. In addition, IL-6 increases invasiveness of colon cancer cells [6] and likely promotes secondary tumour formation through its angiogenic potency. How effective IL-6 is in promoting progression and metastatic spread of colon cancer, depends not only on the extent of basal but, importantly, on the extent of inducible IL-6 expression at certain stages of tumour development.
###end p 11
###begin p 12
###xml 110 111 107 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 112 114 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 136 138 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 139 141 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 180 182 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 210 212 207 209 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 213 215 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 216 218 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 312 317 309 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 481 486 478 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 556 561 <span type="species:ncbi:9606">human</span>
IL-6 expression is highly inducible in different cell types by a variety of cytokines, particularly IL-1beta [9-12], by prostaglandins [12,13], steroid hormones, such as estrogen [14] or 1,25-dihydroxyvitamin D3 [13,15]. Although these substances influence colon carcinoma cell growth, their ability to regulate IL-6 activity in this cell type has not yet been evaluated in detail. The present study was initiated to assess the potential of the aforementioned agents in modulating IL-6 transcriptional activity and protein synthesis at different stages of human colon cancer progression.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human colon carcinoma primary cell clones and cell lines
###end title 14
###begin p 15
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 547 548 547 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 97 102 <span type="species:ncbi:9606">human</span>
From the Caco-2 cell line (ATCC HTB-37), which was originally derived from a well differentiated human colon adenocarcinoma, a number of homogenous and stable Caco-2 clones were established in several laboratories. For the present study, we used the clone Caco-2/AQ, which was derived from the Caco-2/15 clonal line [16] as described before [17]. Caco-2/AQ cells undergo spontaneous differentiation on transition into the post-confluent state, as indicated by a steep rise in differentiation markers, i.e. alkaline phosphatase activity (cf. Table 1).
###end p 15
###begin p 16
###xml 19 24 <span type="species:ncbi:9606">human</span>
Characteristics of human colon carcinoma cell lines
###end p 16
###begin p 17
For details see [5,19,24]. Protein and mRNA expression in confluent cells were classified by visual inspection of Western blots or RT-PCR gels as: nil, -; low, +; medium, ++; high, +++.
###end p 17
###begin p 18
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a </italic>
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>a </italic></sup>
###xml 32 33 32 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 34 36 34 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
a after treatment with 1,25-(OH)2D3 (cf. [19])
###end p 18
###begin p 19
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 524 525 524 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 532 533 532 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
Primary colon adenocarcinoma cell clones COGA-1 and COGA-13 were isolated by Drs. Ernst Wagner and Alexandra Sinski at Boehringer Ingelheim Austria, Vienna, as described in detail elsewhere [18]. From the COGA-1 clonal cell line, which was derived from a Dukes' stage B, pT3, moderately differentiated (i.e. G2) carcinoma, a morphologically homogenous sub-clone, designated COGA-1A, was established and characterised with respect to growth behaviour and degree of differentiation, i.e., alkaline phosphatase activity (Table 1; cf. [5]).
###end p 19
###begin p 20
###xml 127 128 127 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
COGA-13 cells, which were derived from a stage pT2 carcinoma graded G3, exhibit only weak alkaline phosphatase activity (Table 1). In addition to the epithelial cell marker cytokeratin 8 (CK8), COGA-13 cells express also a high level of vimentin [19]; this indicates that they had undergone epithelial-mesenchymal transition.
###end p 20
###begin title 21
Cell culture
###end title 21
###begin p 22
###xml 213 214 207 208 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 696 699 680 683 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 717 720 701 704 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7 </sup>
###xml 725 726 709 710 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 730 733 714 717 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7 </sup>
###xml 755 758 736 739 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 790 793 771 774 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8 </sup>
###xml 804 805 785 786 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 806 808 787 789 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 292 296 <span type="species:ncbi:9913">calf</span>
Human colon cancer cells were routinely cultured in vented tissue culture flasks (Asahi Techno Glass Corporation, Iwaki Scitech division, Tokyo, Japan) at 37degreesC in a humidified atmosphere of 95% air and 5% CO2. Culture medium was DMEM supplemented with 4.0 mM glutamine, 10% (v/v) fetal calf serum (FCS) (heat-inactivated at 56degreesC for 30 min), 20 mM HEPES, 50 U/ml penicillin and 50 mug/ml streptomycin. Cultures were re-fed every 48 h and subcultured serially when approximately 80% confluent. Cells between passages 6 and 24 were cultured for indicated time periods in the absence or presence of one of the following treatments: 5 ng/ml IL-1beta (ImmunoTools, Friesoythe, Germany); 10-6 M indomethacin, 10-7 M PGE2, 10-7 M 17beta-estradiol, 10-6 M NS398 (all from Sigma), and 10-8 M 1,25-(OH)2D3 (a generous gift from Hoffmann-La Roche, Basle, Switzerland).
###end p 22
###begin p 23
###xml 159 160 159 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 406 407 406 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 42 47 <span type="species:ncbi:9606">human</span>
The effect of 0.1 - 100 ng/ml recombinant human (rh) IL-6 (Strathmann Biotec AG, Hamburg, Germany) on cellular proliferation was determined by measurement of [3H]thymidine incorporation into cellular DNA. Degree of cellular differentiation was evaluated in confluent cells from activity of the marker enzyme alkaline phosphatase as described in detail previously [20]: Enzymatic activity was assayed using p-nitrophenol as substrate, and normalised to cellular protein content, which was determined using the BCA Protein Assay Kit (Pierce, Rockford, IL).
###end p 23
###begin title 24
Reverse transcriptase polymerase chain reaction (RT-PCR)
###end title 24
###begin p 25
###xml 517 519 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 680 682 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 839 841 829 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1362 1364 1304 1306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1426 1428 1361 1363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
Total RNA was extracted by using Trizol (GibcoBRL). 2 mug RNA were reverse transcribed with random hexamer primers using a cDNA synthesis kit (SuperScripttrade mark II, Invitrogen). First-strand cDNA was amplified with primer pairs for IL-6, and for the reference gene and epithelial cell marker CK8, respectively (MWG-Biotech AG, Ebersberg, Germany). To amplify a 349 base pair segment of IL-6 cDNA, primer pairs used were 5'-TTC-AAT-GAG-GAG-ACT-TGC-CTG-3' (sense) and 5'-ACA-ACA-ACA-ATC-TGA-GGT-GCC-3' (antisense) [21]. The primer pairs for c-myc were 5'-GGC-TTT-ATC-TAA-CTC-GCT-GT-3' (sense) and 5'-GAG-GTC-ATA-GTT-CCT-GTT-GG-3' (antisense) to amplify a 461 base pair segment [22]. Primer pairs for a 520 base pair segment of the CK8 gene were 5'-TGG-GCA-GCA-GCA-TTA-ACT-TTC-3' (sense) and 5'-AGG-CGA-GAC-TCC-AGC-TCT-AC-3' (antisense) [23]. With the aid of the GeneAmp PCR System 9600 (Perkin-Elmer, Norwalk, CT), the thermocycling conditions began with 94degreesC for 2 min followed by 34 cycles (IL-6) and 30 cycles (CK8), respectively, of: 94degreesC 15 sec, 62degreesC 30 sec, 72degreesC 45 sec, or followed by 30 cycles (c-myc) of 94degreesC 30 sec, 57degreesC 60 sec, 72degreesC 60 sec. Each run was concluded by 10 min at 72degreesC. PCR conditions and primer pairs for cDNA amplification of CYP27B1, CYP24, and VDR were previously provided elsewhere [19], as well as for cDNA amplification of ER-alpha and ER-beta [24]. A 1:1 mixture of PCR products and CK8 amplificates from the same sample was separated on 2% agarose gels and then visualised with ethidium bromide. No bands were visible in negative controls that were performed for all primer pairs.
###end p 25
###begin title 26
Determination of protein
###end title 26
###begin p 27
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
IL-6 concentrations in cell culture supernatants were determined by enzyme-linked immunosorbent assay (ELISA) (eBioscience, San Diego, CA) according to the protocol of the manufacturer. Since preliminary data had indicated that some clones might produce IL-6 in amounts close to the detection limit of the assay (2 pg/ml IL-6), we added a constant background of 10 pg/ml IL-6 to all samples to improve intra-assay accuracy. Immunoblotting for CK8, vimentin, cyclin D1, and p27 has been described elsewhere [19].
###end p 27
###begin title 28
DNA isolation and sequence analysis
###end title 28
###begin p 29
###xml 971 973 952 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1371 1372 1352 1353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human genomic DNA was extracted from confluent colorectal cell clones. Cells were trypsinised and washed twice with PBS before suspension in extraction buffer (50 mM Tris / HCl pH 8, 100 mM EDTA, 100 mM NaCl, 1% SDS, 0.5 mg/ml proteinase K) and overnight shaking on an Eppendorf shaker at 55degreesC. Saturated NaCl (6 M) (a third of the volume of extraction buffer) was added before centrifugation at 13000 rpm for 10 min on a Microfuge Lite Centrifuge (Beckman Coulter, Fullerton, CA). The supernatant was treated with approximately the same amount of isopropanol, shaken thoroughly, and centrifuged (13000 rpm, 5 min). Thereafter, the pellet was washed with EtOH (70%, v/v), resuspended in 400 mul TE buffer (10 mM Tris, pH 8 / 1 mM EDTA), and agitated on an Eppendorf shaker at 65degreesC for 15 min. DNA was stored at -20degreesC until analysed. DNA amplification was performed with a GeneAmp PCR System 9600 (Perkin-Elmer, Foster City, CA) as described previously [25]. PCR products were subsequently purified using the Centri Sep 96 system (Princeton Separations, NJ), and thereafter subjected to sequencing using Big Dye Terminator Cycling Sequencing kit, version v3.1, and the ABI Prism 310 Genetic Analyzer (Applied Biosystems, Foster City, CA) according to the manufacturer's recommendation. Primers for amplification and sequencing were applied as listed in [9].
###end p 29
###begin title 30
Statistical analysis
###end title 30
###begin p 31
###xml 346 347 346 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 469 471 469 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 483 485 483 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 498 500 498 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Statistical analyses were conducted with use of the software packages S-PLUS (version 4.5, Lucent Technologies Inc., Murray Hill, NJ) and SPSS (version 12.0.1, SPSS Inc., Chicago, IL). The normal distribution of all data sets was verified with the aid of the one-sample Kolmogorov-Smirnov goodness of fit-test; as a result the unpaired Student's t-test was used throughout. With a confidence level of 0.95, differences were considered statistically significant with *, P < 0.05; **, P < 0.01; ***, P < 0.001.
###end p 31
###begin title 32
Results
###end title 32
###begin title 33
###xml 14 19 <span type="species:ncbi:9606">human</span>
Validation of human colon carcinoma cell clone models
###end title 33
###begin p 34
###xml 269 270 269 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 279 280 279 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 881 882 877 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 34 39 <span type="species:ncbi:9606">human</span>
We had availed ourselves of three human colon carcinoma-derived cell clones, i.e. Caco-2, COGA-1A, and COGA-13, which we had characterised previously with respect to their log phase growth behaviour and to expression of the differentiation marker alkaline phosphatase [5] (Table 1). For the purpose of the present study, the proliferative potential was evaluated by determination of the cell cycle regulators, cyclin D1, which promotes G1/S transition, and p27, a cdk-inhibitor. We also determined expression of the epithelial and mesenchymal cell markers, cytokeratin 8 (CK8) and vimentin, respectively. Furthermore, we checked for expression of the vitamin D metabolising enzymes, 25-hydroxy-vitamin D-24-hydroxylase (CYP24) and 25-hydroxy-vitamin D-1alpha-hydroxylase (CYP27B1), as well as of the vitamin D receptor (VDR), and the estrogen receptors (ER)-alpha and -beta (Table 1).
###end p 34
###begin p 35
###xml 456 457 456 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Consistent with their origin from a well differentiated tumour, Caco-2 cells exhibited the highest level of the differentiation marker alkaline phosphatase. In contrast, enzyme activity was low in COGA-1, and was barely detectable in COGA-13 cells. Cellular differentiation declined in the order Caco-2 > COGA-1A > COGA-13. The proliferative potential varied inversely with differentiation, as indicated by the rise in cyclin D1 and the drop in p27 (Table 1).
###end p 35
###begin p 36
###xml 119 120 119 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 362 363 362 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
All three cell clones were of epithelial origin according to their expression of the epithelial cell marker CK8 (Table 1). Little vimentin was detected in Caco-2 and COGA-1A cells, whereas in COGA-13, expression of vimentin exceeded that of CK8. This indicates a high degree of epithelial/mesenchymal transition in these least differentiated cancer cells (Table 1).
###end p 36
###begin p 37
###xml 29 30 29 30 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 234 236 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 337 338 334 335 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 339 341 336 338 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 353 354 347 348 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 763 765 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
The findings listed in Table 1 also indicate that all three clones, notwithstanding marked differences in growth characteristics and degree of differentiation, express the VDR, and, as typical for colon epithelial cells, the ER-beta [24]. Consequently, all three clones can be expected to respond to the receptor ligands, i.e., 1,25-(OH)2D3 and 17beta-E2. Also, all three clones expressed the vitamin D metabolising enzymes, 25-hydoxyvitamin D-24-hydroxylase (CYP24) and 25-hydoxyvitamin D-1alpha-hydroxylase (CYP27B1), though at markedly different levels. Of note, CYP27B1 was abundant in Caco-2/AQ cells, as is typical for rather differentiated colon carcinomas, whereas CYP24 was overexpressed in COGA-13 cells consistent with a low degree of differentiation [26].
###end p 37
###begin title 38
###xml 89 90 86 87 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 101 102 98 99 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 103 104 100 101 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 118 119 112 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 36 41 <span type="species:ncbi:9606">human</span>
IL-6 mRNA and protein expression in human colon carcinoma cells: effects of IL-1beta, PGE2, 1,25-(OH)2D3, and 17beta-E2
###end title 38
###begin p 39
###xml 154 155 154 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 118 123 <span type="species:ncbi:9606">human</span>
RT-PCR analysis revealed a distinct, i.e., clone-specific, pattern of basal and stimulated expression of IL-6 mRNA in human colon carcinoma cells (Figure 1): As had been observed previously, carcinoma cell clones derived from well to moderately differentiated cancers, i.e. Caco-2 and COGA-1A, expressed only small amounts of IL-6, as compared with COGA-13 cells, which are derived from a poorly differentiated tumour. In these cells, which had already undergone substantial epithelial-mesenchymal transition, IL-6 is conspicuously overexpressed.
###end p 39
###begin p 40
###xml 135 138 135 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 156 159 156 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7 </sup>
###xml 164 165 164 165 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 169 172 169 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8 </sup>
###xml 183 184 183 184 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 185 186 185 186 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 190 193 190 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7 </sup>
###xml 203 204 200 201 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 306 311 300 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 485 487 477 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 623 625 613 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 637 639 627 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 652 654 642 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 673 674 663 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 60 65 <span type="species:ncbi:9606">human</span>
Basal and stimulated expression of IL-6 mRNA and protein in human colon carcinoma cell clones. Additions to the culture medium were: 10-6 M indomethacin, 10-7 M PGE2, 10-8 M 1,25-(OH)2D3, 10-7 M 17beta-E2, 5 ng/ml IL-1beta. Upper part: Representative RT-PCR amplifications of mRNA transcripts specific for IL-6 (culture time 4 h). Expression of epithelial cell marker CK8 is shown for comparison. Lower part: IL-6 release into medium during 24 h culture period. Data are means +/- SD, n >/= 4. Note that changes in IL-6 secretion by COGA-13 cells are given on a logarithmic scale. Statistically significant differences: *, P < 0.05; **, P < 0.01; ***, P < 0.001 (Student's t-test).
###end p 40
###begin p 41
###xml 140 141 137 138 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 142 143 139 140 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 211 212 208 209 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 294 295 288 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
In Caco-2/AQ cells, IL-6 gene activity and protein synthesis were up-regulated only by IL-1beta, whereas COGA-1A responded only to 1,25-(OH)2D3. In COGA-13 cells, IL-6 levels were increased to some extent by PGE2, whereas IL-1beta increased IL-6 expression by three orders of magnitude (Figure 1).
###end p 41
###begin p 42
###xml 104 105 101 102 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 116 117 113 114 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 118 119 115 116 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 133 134 127 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 226 227 220 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 248 253 242 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 412 413 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 592 593 583 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 686 689 677 680 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7 </sup>
###xml 694 696 685 687 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
A more detailed picture of clonal sensitivity towards modulators of IL-6 was obtained when IL-1beta, PGE2, 1,25-(OH)2D3, and 17beta-E2, singly or in appropriate combinations, were added to colon carcinoma cell cultures (Table 2). Overexpression of IL-6 by the COGA-13 clone became apparent also at the protein level, as COGA-13 cells produced at least four times more IL-6 than Caco-2/AQ or COGA-1A cells (Table 2). In none of the clones, IL-6 production, regardless of whether basal or IL-1beta-induced, was changed when endogenous prostaglandin synthesis was blocked by indomethacin (Table 2) or by the cyclooxygenase (COX)-2 inhibitor, NS398 (not shown). As mentioned before, when 10-7 M PGE2 was added to COGA-13 cultures, a small increment in IL-6 release was observed.
###end p 42
###begin p 43
###xml 42 47 <span type="species:ncbi:9606">human</span>
Effect of modulators of IL-6 synthesis in human colon carcinoma cell clones
###end p 43
###begin p 44
###xml 59 62 59 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 68 69 68 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 73 76 73 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7 </sup>
###xml 88 89 88 89 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 90 91 90 91 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 95 98 95 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8 </sup>
###xml 109 110 106 107 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 114 117 111 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7 </sup>
Additions to culture medium for 24 h were: indomethacin, 10-6 M; PGE2, 10-7 M; 1,25-(OH)2D3, 10-8 M; 17beta-E2, 10-7 M; IL-1beta, 5 ng/ml.
###end p 44
###begin p 45
###xml 8 10 5 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 193 194 187 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
17beta-E2 was effective in COGA-13 cultures, where it reduced basal IL-6 release by one third. However, the hormone did not alter the extensive stimulation by IL-1beta of IL-6 synthesis (Table 2).
###end p 45
###begin title 46
Sequence analysis of IL-6 promoter
###end title 46
###begin p 47
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 136 140 136 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6</italic>
###xml 163 165 163 165 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 166 167 166 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
We analysed the IL-6 gene promoter for the presence of specific polymorphisms that are known to influence transcriptional regulation of IL-6, e.g., by IL-1 and PGE2 [9] (Table 3).
###end p 47
###begin p 48
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 68 73 <span type="species:ncbi:9606">human</span>
Genotypes at three common polymorphic sites of the IL-6 promoter in human colon carcinoma cell clones
###end p 48
###begin title 49
###xml 45 50 <span type="species:ncbi:9606">human</span>
IL-6 effect on growth and differentiation of human colon carcinoma cell clones
###end title 49
###begin p 50
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 386 387 386 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 441 445 441 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-my</italic>
###xml 487 489 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
To evaluate the mitogenic potency of IL-6 in Caco-2/AQ, COGA-1A and COGA-13 cell cultures, graded concentrations of the cytokine (0-100 ng/ml) were added to the medium for 72 h. A dose dependent increase in cell division was observed only in Caco-2/AQ cells, whereas the growth rate in COGA-1A and GOGA-13 was unaltered (Figure 2A). All three clones are endowed with the IL-6 receptor [5], but IL-6 proliferative signaling was transduced to c-myc expression only in Caco-2 cells (Figure 2B): IL-6 expression rose about fourfold after 24 h incubation with 100 ng/ml rhIL-6 (Figure 2C).
###end p 50
###begin p 51
###xml 130 131 130 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 238 240 236 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 357 359 355 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 372 374 370 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 393 394 391 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 421 427 419 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc </italic>
###xml 652 658 650 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc </italic>
(A) Effect of hIL-6 on growth rate of confluent Caco-2/AQ, COGA-1A, and COGA-13 cells. Cellular proliferation was evaluated from [3H]thymidine incorporation into DNA after 72 h incubation with rhIL-6 (0-100 ng/ml). Data are means +/- SD (n = 4 - 16) and expressed as multiples of IL-6-free controls. Statistically significant differences from controls: **, P < 0.01; ***, P < 0.001 (Student's t-test). (B) Time-course of c-myc mRNA expression in confluent Caco-2/AQ, COGA-1A, and COGA-13 clones during incubation with 100 ng/ml rhIL-6. Expression of the epithelial cell marker CK8 is shown for comparison. (C) Densitometric evaluation of expression of c-myc in relation to CK8 as shown in (B): basal expression ratios in zero time controls were set to 1.
###end p 51
###begin p 52
###xml 27 30 27 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8 </sup>
###xml 41 42 41 42 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 43 45 43 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 241 242 241 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 254 255 254 255 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 256 258 256 258 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 392 393 392 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
In Caco-2 cell cultures, 10-8 M 1,25-(OH)2D3 abolished the growth stimulatory effect of 10 ng/ml IL-6. Still a 50% reduction was observed when cell division was stimulated by IL-6 at the supraphysiological concentration of 100 ng/ml (Figure 3). 1,25-(OH)2D3 completely prevented any inhibitory effect of IL-6 on the activity of the differentiation marker enzyme, alkaline phosphatase (Figure 4).
###end p 52
###begin p 53
###xml 19 20 19 20 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 21 23 21 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 26 29 26 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8 </sup>
###xml 143 144 143 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 255 257 253 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 322 324 320 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 336 338 334 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 356 357 354 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Effect of 1,25-(OH)2D3 (10-8 M) on IL-6-related proliferation of confluent Caco-2/AQ cells. Culture time was 72 h. Cell growth was assayed by [3H]thymidine incorporation into cellular DNA (normalised to total protein). Data are expressed as means +/- SD, n = 4 - 7. Statistically significant differences from controls: *, P < 0.05; **, P < 0.01 (Student's t-test).
###end p 53
###begin p 54
###xml 19 20 19 20 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 21 23 21 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 160 161 160 161 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 162 163 162 163 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 167 170 167 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8 </sup>
###xml 389 391 386 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 439 441 436 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 454 456 451 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 475 476 472 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Effect of 1,25-(OH)2D3 on rhIL-6-induced inhibition of differentiation of Caco-2/AQ cells. Incubation time was 72 h. Concentrations in culture medium: 1,25-(OH)2D3, 10-8 M; rhIL-6, 100 ng/ml. Cellular differentiation was evaluated from activity of the marker enzyme alkaline phosphatase. Data were calculated as mU/mug cellular protein and expressed as "percent of control" (means +/- SD, n = 8). Statistically significant differences: *, P < 0.05; ***, P < 0.001 (Student's t-test).
###end p 54
###begin title 55
Discussion
###end title 55
###begin p 56
###xml 67 72 67 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 379 380 379 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 84 89 <span type="species:ncbi:9606">human</span>
###xml 464 469 <span type="species:ncbi:9606">human</span>
The purpose of the present study was to evaluate the regulation of IL-6 activity in human colon carcinoma cells by classical modulators in respect to possible consequences for tumour progression. In this regard, it is important to note that each of the cell clones used in the present study, i.e., Caco-2/AQ, COGA-1A, and COGA-13, according to the characteristics shown in Table 1, represents a valid model system for studies on differentiation-related changes of human colon cancer cell functions during tumour progression.
###end p 56
###begin p 57
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 131 132 131 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 212 213 212 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 267 268 267 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 518 523 518 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 724 725 724 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 149 154 <span type="species:ncbi:9606">human</span>
###xml 286 291 <span type="species:ncbi:9606">human</span>
Overexpression of IL-6 seems to be a hallmark of advanced tumour progression, since it has been observed, apart from colon cancer [5], also in other human malignancies, e. g., multiple myeloma, Kaposi's sarcoma [9], or glioblastoma [27]. From data reported in Figure 1 it is clear that human colon carcinoma cell clones derived from well to moderately differentiated tumours, i.e. Caco-2/AQ and COGA-1A, express relatively little IL-6, particularly when compared to the rather undifferentiated clone COGA-13. Not only IL-6 gene activity differs according to the degree of differentiation, but also the extent of unstimulated translation into protein is at least four times higher in COGA-13 than in Caco-2 or COGA-1A (Table 2).
###end p 57
###begin p 58
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 168 169 161 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 170 172 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 214 219 207 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 361 363 354 356 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 368 371 361 364 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7 </sup>
###xml 390 395 383 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 524 525 517 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 545 550 538 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 556 558 549 551 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 694 696 687 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 810 815 800 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 855 856 845 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 975 977 962 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1116 1118 1103 1105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1148 1153 1135 1140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 889 894 <span type="species:ncbi:9606">human</span>
The promoter region of the IL-6 gene contains a number of binding sites for transcription factors such as NFIL6 (C/EBPbeta), NFkappaB, Fos/Jun (AP-1), CRBP, CREB etc. [9-12]. This explains the basic sensitivity of IL-6 towards classical transcription modulating factors such as prostaglandins, cytokines, steroid hormones etc. It is interesting to note that PGE2 at 10-7 M had no effect on IL-6 expression and protein synthesis in Caco-2 and COGA-1A cells, and induced only a relatively small change in COGA-13 cells (Table 2). Insensitivity of IL-6 to PGE2 can be deduced also from the observation that in all three cell clones, though they are endowed with cyclooxygenase-2 (COX-2) activity [28], suppression of endogenous PG synthesis by indomethacin or NS398 had no effect on basal and IL-1beta-stimulated IL-6 expression and protein secretion (Table 2). We conclude from this that in human colon cancer cells, endogenous PG production, even when stimulated by IL-1beta [28], is too low to affect IL-6 production, and that, conversely, the chemopreventive effect on colon cancer development of COX-2 inhibitors [29] does not involve changes of IL-6 expression.
###end p 58
###begin p 59
###xml 112 113 105 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 116 121 109 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 236 238 226 228 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 251 252 241 242 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 253 255 243 245 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 263 264 253 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 272 273 262 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 284 286 271 273 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 614 616 601 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 656 661 643 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 135 140 <span type="species:ncbi:9606">human</span>
###xml 575 580 <span type="species:ncbi:9606">human</span>
Although all cell types investigated had been shown to express ER-alpha and -beta as well as the VDR (cf. Table 1), IL-6 expression in human colon carcinoma cells was only modestly, if at all, influenced by the steroid hormones 17beta-E2 and 1,25-(OH)2D3 (Figure 1; Table 2). 17beta-E2 had no effect on IL-6 synthesis in Caco-2/AQ and COGA-1A cells, and inhibited IL-6 production by highly undifferentiated COGA-13 cells only to an extent which makes efficient suppression of IL-6 production in high grade cancers by oestrogens very unlikely. This implies that prevention of human colorectal cancer by oestrogens [30] does not involve any direct effect on IL-6 expression.
###end p 59
###begin p 60
###xml 23 24 23 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 25 27 25 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 149 150 149 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 185 186 185 186 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 187 189 187 189 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 392 393 392 393 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 394 396 394 396 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 421 422 421 422 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 423 424 423 424 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 611 613 611 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 631 632 631 632 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 633 635 633 635 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 717 718 717 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 782 783 782 783 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 784 786 784 786 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 863 864 863 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 582 587 <span type="species:ncbi:9606">human</span>
Resistance to 1,25-(OH)2D3 in VDR-positive cells can be due to rapid degradation of the steroid catalysed by the 25-(OH)-D-24-hydroxylase (cf. Table 1). This could explain why 1,25-(OH)2D3 has no effect on IL-6 production in COGA-13, or only a marginal one in COGA-1A cells, but this is certainly not valid for Caco-2 cells, which are generally responsive to VDR-mediated actions of 1,25-(OH)2D3 [19]. The small 1,25-(OH)2D3-related increment of IL-6 production by COGA-1A cells seems to be without relevance for the anti-mitogenic and pro-differentiating effects of the hormone in human colon carcinoma cells [19], since 1,25-(OH)2D3 effectively suppressed IL-6-induced growth in differentiated Caco-2 cells (Figure 3). At the same time, the pro-differentiating action of 1,25-(OH)2D3 was completely preserved, even at extremely high IL-6 concentrations (Figure 4).
###end p 60
###begin p 61
###xml 28 30 25 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 43 44 40 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 45 47 42 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 61 66 58 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 251 256 245 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 430 435 424 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 451 456 445 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 459 460 453 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 600 602 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 628 633 622 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 741 746 735 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 781 783 775 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 821 826 815 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 829 831 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 897 902 891 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 857 865 <span type="species:ncbi:9606">patients</span>
###xml 955 963 <span type="species:ncbi:9606">patients</span>
The inefficiency of 17beta-E2 and 1,25-(OH)2D3 in modulating IL-6 transcriptional activity could result from impaired or abrogated signal transduction downstream of the ER-beta or VDR, respectively, but may also be due to clone-specific expression of IL-6 gene variants. This could be the consequence of acquisition of mutations during tumour development and progression, or, respectively, caused by specific polymorphisms in the IL-6 promoter. Terry et al. [9] had identified four polymorphic sites, which influence not only basal but also regulatable transcription in a complex cooperative manner [12]. For example, the -174C IL-6 haplotype is less efficiently translated into protein than its -174G counterpart, and conveys resistance of IL-6 to the stimulatory action of IL-1 [12]. This may be the reason why Belluco et al. [31] found that colon cancer patients carrying the -174G polymorphic IL-6 gene had significantly higher IL-6 serum levels than patients with the -174C genotype, particularly in the presence of hepatic metastases.
###end p 61
###begin p 62
###xml 45 46 45 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 97 102 97 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 297 302 297 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 305 306 305 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 498 502 498 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6</italic>
###xml 572 573 572 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 663 664 660 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 751 756 748 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 779 780 773 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 914 919 908 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
Our search for promoter polymorphisms (Table 3) showed that all cell clones investigated express IL-6 variants which were identical only at -572 but different from each other at sites -597 and -174. The -597A/-572G/-174C haplotype, as solely present in COGA-13 cells, has been identified by Terry et al. [9] as the one which, when transfected in ECV304 cells, shows a comparable high transcriptional activity (cf. also [12]). This may explain why COGA-13 cells, particularly since they overexpress IL-6, produce significantly more IL-6 than Caco-2 or COGA-1A cells (Table 2). However, the same -597A/-572G/-174C haplotype shows the least sensitivity to IL-1beta [9]. Therefore, the striking difference in the regulation of transcriptional activity of IL-6 by IL-1beta (cf. Table 2) could only be due to cooperativity with still unknown promoter polymorphisms or, much more likely, due to mutational changes in the IL-6 gene acquired during progression through the adenoma/carcinoma sequence. These questions can only be answered when more information on polymorphic sites and cancer-related mutations in the IL-6 gene will be available.
###end p 62
###begin p 63
###xml 106 114 <span type="species:ncbi:9606">patients</span>
###xml 696 704 <span type="species:ncbi:9606">patients</span>
From the results of the present study it is conceivable that a highly critical situation for colon cancer patients may arise, when COGA-13-type cells become abundant in a cancerous lesion. If unopposed, massive release of IL-6 under the stimulation by IL-1beta might accelerate tumour progression to high stage malignancy by paracrine proliferative action on IL-6-responsive, i.e., still differentiated cells. At present, we are unaware of any means by which IL-6 secretion from undifferentiated colon cancer cells can be effectively suppressed. Alternatively, development of anti-IL-6 or anti-IL-6 receptor monoclonal antibodies could be beneficial for future adjuvant immune therapy for cancer patients with genetic predisposition for IL-6 overexpression. In any case, screening for carriers of IL-6 gene variants with high susceptibility to transcriptional dysregulation by IL-1beta should be considered for identification of individuals with high-risk for therapy-resistant colorectal cancer.
###end p 63
###begin title 64
Conclusion
###end title 64
###begin p 65
###xml 273 279 270 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc </italic>
###xml 29 34 <span type="species:ncbi:9606">human</span>
Evidence is provided that in human colon cancer, undifferentiated tumour cells are the main source of IL-6. The cytokine can be released in massive amounts, particularly when its expression is up-regulated by IL-1beta. Transduction of IL-6 signalling into up-regulation of c-myc expression results in enhanced growth of colon carcinoma cells.
###end p 65
###begin title 66
Competing interests
###end title 66
###begin p 67
The authors declare that they have no competing interests.
###end p 67
###begin title 68
Authors' contributions
###end title 68
###begin p 69
###xml 263 268 263 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
WB carried out the proliferation assays, RT-PCR and protein analyses, and performed the statistical analyses, GB helped with the cell culture experiments for characterisation of the colon carcinoma cell clones, GF carried out the analyses of polymorphisms in the IL-6 gene promoter, HSC participated in the design of the study and coordinated all the experimental work, MP conceived of the study, participated in its design and drafted the manuscript. All authors read and approved the final manuscript.
###end p 69
###begin title 70
Pre-publication history
###end title 70
###begin p 71
The pre-publication history for this paper can be accessed here:
###end p 71
###begin p 72

###end p 72
###begin title 73
Acknowledgements
###end title 73
###begin p 74
The present study was financed in part by Grant No. 9401 of the Jubilaumsfonds der Osterreichischen Nationalbank (Austrian National Bank). W. B. was supported in part by a scholarship (Forschungsstipendium) of the Medical University of Vienna. We thank Dr. Felix Bronner, Professor emeritus at the University of Connecticut at Farmington, for his valuable help in preparing the manuscript.
###end p 74
###begin article-title 75
Interleukin 6 and its receptor: ten years later
###end article-title 75
###begin article-title 76
The role of cytokines and chemokines on tumor progression: a review
###end article-title 76
###begin article-title 77
###xml 48 53 <span type="species:ncbi:9606">human</span>
Interleukin-6 and its receptor are expressed in human intestinal epithelial cells
###end article-title 77
###begin article-title 78
###xml 69 74 <span type="species:ncbi:9606">human</span>
Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells
###end article-title 78
###begin article-title 79
###xml 78 83 <span type="species:ncbi:9606">human</span>
Differentiation-dependent expression and mitogenic action of interleukin-6 in human colon carcinoma cells: Relevance for tumour progression
###end article-title 79
###begin article-title 80
###xml 50 55 <span type="species:ncbi:9606">human</span>
Influence of interleukin-6 on the invasiveness of human colorectal carcinoma
###end article-title 80
###begin article-title 81
Interleukin-1beta (IL-1beta) and IL-6 modulate insulin-like growth factor-binding protein (IGFBP) secretion in colon cancer epithelial (Caco-2) cells
###end article-title 81
###begin article-title 82
Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer
###end article-title 82
###begin article-title 83
Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation
###end article-title 83
###begin article-title 84
###xml 25 29 25 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 29 30 26 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 18 23 <span type="species:ncbi:9606">human</span>
Activation of the human "beta2-interferon/hepatocyte-stimulating factor/interleukin 6" promoter by cytokines, viruses, and second messenger agonists
###end article-title 84
###begin article-title 85
Constitutive and interleukin-1 (IL-1)-inducible factors interact with the IL-1-responsive element in the IL-6 gene
###end article-title 85
###begin article-title 86
The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis
###end article-title 86
###begin article-title 87
###xml 31 33 31 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
Differential stimulation by PGE2 and calcemic hormones of IL-6 in stromal/osteoblastic cells
###end article-title 87
###begin article-title 88
###xml 2 6 2 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 41 46 38 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#945;</italic>
###xml 68 70 61 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 136 141 <span type="species:ncbi:10090">mouse</span>
17beta-Estradiol antagonizes effects of 1alpha,25-dihydroxyvitamin D3 on interleukin-6 production and osteoclast-like cell formation in mouse bone marrow primary cultures
###end article-title 88
###begin article-title 89
###xml 23 28 23 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#945;</italic>
###xml 51 53 47 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 83 88 <span type="species:ncbi:9606">human</span>
Regulatory effects of 1alpha, 25-dihydroxyvitamin D3 on the cytokine production of human peripheral blood lymphocytes
###end article-title 89
###begin article-title 90
###xml 56 61 <span type="species:ncbi:9606">human</span>
Clonal analysis of sucrase-isomaltase expression in the human colon adenocarcinoma Caco-2 cells
###end article-title 90
###begin article-title 91
###xml 23 28 23 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#945;</italic>
###xml 43 47 39 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
Biological effects of 1alpha-hydroxy- and 1beta-(hydroxymethyl)-vitamin D compounds relevant for potential colorectal cancer therapy
###end article-title 91
###begin article-title 92
Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers
###end article-title 92
###begin article-title 93
###xml 28 30 24 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
1alpha,25-Dihydroxyvitamin D3 downregulates CYP27B1 and induces CYP24A1 in colon cells
###end article-title 93
###begin article-title 94
An inter-laboratory study to evaluate the effects of medium composition on the differentiation and barrier function of Caco-2 cell lines
###end article-title 94
###begin article-title 95
Rac1 mediates STAT3 activation by autocrine IL-6
###end article-title 95
###begin article-title 96
###xml 67 72 <span type="species:ncbi:9606">human</span>
Co-overexpression of DEAD box protein rck/p54 and c-myc protein in human colorectal adenomas and the relevance of their expression in cultured cell lines
###end article-title 96
###begin article-title 97
###xml 21 26 <span type="species:ncbi:9606">human</span>
Mutation analysis of human cytokeratin 8 gene in malignant rhabdoid tumor: a possible association with intracytoplasmic inclusion body formation
###end article-title 97
###begin article-title 98
###xml 79 84 <span type="species:ncbi:9606">human</span>
Genistein and 17beta-estradiol, but not equol, regulate vitamin D synthesis in human colon and breast cancer cells
###end article-title 98
###begin article-title 99
###xml 59 64 <span type="species:ncbi:9606">women</span>
Analysis of an interleukin-6 gene promoter polymorphism in women with endometriosis by pyrosequencing
###end article-title 99
###begin article-title 100
###xml 35 40 <span type="species:ncbi:9606">human</span>
25-Hydroxy-vitamin D metabolism in human colon cancer cells during tumor progression
###end article-title 100
###begin article-title 101
###xml 72 80 <span type="species:ncbi:9606">patients</span>
Interleukin-6 gene amplification and shortened survival in glioblastoma patients
###end article-title 101
###begin article-title 102
Up-regulation of cyclooxygenase-2 by interleukin-1beta in colon carcinoma cells
###end article-title 102
###begin article-title 103
Molecular pathology of cyclooxygenase-2 in neoplasia
###end article-title 103
###begin article-title 104
###xml 72 77 <span type="species:ncbi:9606">women</span>
###xml 106 111 <span type="species:ncbi:9606">Women</span>
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial
###end article-title 104
###begin article-title 105
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-174 G&gt;C </italic>
###xml 25 39 25 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">interleukin 6 </italic>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
-174 G>C polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer
###end article-title 105

